Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Congenital fibrinogen deficiency market will surpass $800 million across the 3MM by 2031, driven by demand for plasma-derived therapies, says GlobalData

The congenital fibrinogen deficiency (CFD) market is forecast to increase from $673 million in 2021 to over $800 million in 2031 at a compound annual growth rate (CAGR) of 1.7% across the three major markets (3MM*). Growth will be driven by the launch of improved human fibrinogen concentrate (HFC) products, the large market potential for HFC […]
Read more

Bispecific antibodies will threaten cell therapy in multiple myeloma in 2023, says GlobalData

A relatively novel class of drugs called bispecific T-cell engagers (BiTEs) present a serious threat to the market position of Bristol Myers-Squibb’s Abecma (ide-cel) for the treatment of relapsed or refractory multiple myeloma (RRMM) as they leverage clinical advantages such as improved duration of response to therapy and quicker administration, says GlobalData, a leading data […]
Read more

Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData

The current diabetic neuropathic pain treatment paradigm includes many established analgesics that provide symptomatic relief. However, as these therapies do not target the pathophysiological mechanisms underlying the pain, they typically only work in a subset of patients, and provide only partial pain relief. Furthermore, the established marketed analgesics have been associated with poor safety profiles. […]
Read more

Historically unimpressive field of therapeutic cancer vaccines gets revitalized with Moderna and Merck mRNA data, says GlobalData

Historically, therapeutic cancer vaccines have demonstrated minimal efficacy. However, for the first time, an anti-cancer vaccine has shown significant promise in a clinical trial. The combination therapy of Moderna’s mRNA vaccine “mRNA-4157/V940” in combination with Merck & Co’s anti-PD-1 therapy “Keytruda”  has reportedly cut the risk of melanoma recurrence or death by 44% compared to […]
Read more

Strong uptake expected for AbbVie’s Vraylar in major depressive disorder market, says GlobalData

Following the news that AbbVie’s Vraylar (cariprazine) gained approval from the FDA for the adjunctive treatment of major depressive disorder (MDD) in adults; Pippa Salter, Senior Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “In the MDD market, there is a need for therapies that can treat patients who are inadequately responding […]
Read more

Dupixent’s safety concerns unlikely to impact prescriptions, says GlobalData

Recently, the UK’s Medicines, and Healthcare Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Sanofi & Regeneron’s Dupixent, a drug used in the treatment of numerous allergic indications. Leading data and analytics company, GlobalData, notes that, although this safety update will likely raise physician vigilance regarding long-term Dupixent […]
Read more

CanSino Biologics inhaled vaccine Convidecia Air to gain good momentum amid plans to boost elderly vaccination in China, says GlobalData

In a clear shift away from its long-held stringent zero-COVID policy, China has recently relaxed rules that contained the spread of the virus but impacted the world’s second largest economy. Subsequently, the National Health Commission (NHC) pledged to step up vaccination among the elderly. Against this backdrop, considering that CanSino Biologics’ inhaled vaccine Convidecia Air […]
Read more

50% of healthcare industry professionals would prioritize investing in AI in the next two years, finds GlobalData survey

According to a survey by GlobalData, 50% of healthcare industry professionals would prioritize artificial intelligence (AI) among other emerging technologies for their investments in the next two years. The leading data and analytics company notes that AI has been trending as the leading future investment target in the pharmaceutical industry since 2018, gaining a 6% […]
Read more

GOSH TvT CAR7 Phase I: Positive trial results with CRISPR base-edited CAR-T cells is a significant step in treating cancer, says GlobalData

Following the news that the first patient in the UCL Great Ormond Street Insititute of Child Health’s (GOSH) Phase I TvT CAR7 trial to treat pediatric relapsed/refractory T-cell acute lymphoblastic leukemia, has gone into remission; James Donagher, Oncology & Hematology Analyst at GlobalData, a leading data and analytics company, offers his view: “While the GOSH […]
Read more

Potential prophylactic antibiotic use for Strep A infections highlights need for vaccine, says GlobalData

Following the news that, amid rising cases and deaths nationally, antibiotics could be administered prophylactically in UK schools with cases of streptococcus A (Strep A); Fiona Chisholm, Associate Director at GlobalData, a leading data and analytics company, offers her view: “Health officials are under increased pressure to curb inappropriate use of antibiotics and rarely give […]
Read more

Merck’s Imago Biosciences acquisition to go head-to-head with GSK in increasingly competitive blockbuster market, says GlobalData

Following the news that Merck is to acquire Imago Biosciences, a clinical-stage biotech developing the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for the treatment of myelofibrosis (MF); Sam Warburton, Oncology Analyst at GlobalData, a leading data and analytics company, offers his view: “Big pharma appears to be setting its sights on the relatively small but potentially […]
Read more

Cannabinoid-based drug developers face challenging regulatory landscape despite increasing use of cannabinoid receptors, says GlobalData

A surge in the cannabinoid drug pipeline has led to cannabinoid receptors becoming the most popular target in preclinical development this year, says GlobalData. However, the leading data and analytics company notes that the current regulatory landscape poses a challenge for cannabinoid-based drug developers and regulators. CB1 receptors are the joint first most popular target in […]
Read more

Technology partnerships around genomic profiling to drive cancer care towards precision medicine in India, says GlobalData

As cancer treatment is evolving globally, the regular approach of one-size-fits-all is being challenged with precision medicine, a concept that involves genetic screening of the patient to allow doctors to select an appropriate treatment for a better outcome. In this context, the recent alliances forged around the development of genomic profiling tests in India are […]
Read more
1 … 41 42 43 44 45 … 110